Day Two

Explore the Agenda

Pre-Conference Day

Monday, 23rd February

Day One

Tuesday, 24th February

Day Two

Wednesday, 25th February

Post-Conference Day

Thursday, 26th February

7:30 am Check In, Morning Coffee & Light Refreshments

8:25 am Chair’s Opening Remarks

Tackling the Necessity for Bioconjugate Design & Payload Innovation to Secure the Future of ADCs as Clinically Meaningful Oncology Therapies

8:30 am Fuelling the Next Generation of ADCs: Protein Alkylation Payloads & the Broader ADC Innovation Imperative

Bob Lutz

Chief Scientific Officer, Iksuda Therapeutics

Highlighting the strategic need for diversified payload platforms to drive sustainable ADC pipeline growth and maintain market competitiveness
Positioning protein alkylation as a differentiated and emerging modality within the evolving ADC payload landscape
Showcasing the unique mechanism of action and therapeutic potential of Iksuda Therapeutics’ ProAlk™ payload

9:00 am Synaffix/Lonza End-to-End Offering to Best-in-Class Targeted-Therapies Based on GlycoConnect® & HydraSpace® Technologies

Floris van Delft

Head, R&D, Synaffix, a Lonza Company

Exploring how GlycoConnect® and HydraSpace® technologies enable ADCs with best-in-class therapeutic potential
Sharing clinical development insights on the rapidly advancing pipeline of GlycoConnect® ADCs by partners
Discussing technology expansion towards bispecific (bYlok®) and dual warhead ADCs with compelling in vivo data
Presenting unprecedented mRNA exon skipping and dystrophin restoration in preclinical mouse model for Duchenne muscular dystrophy

9:30 am Spotlighting Efficacy & Safety Profiles of Dual Payload ADCs Featuring Novel Linker Payloads to Overcome Resistance Mechanisms

Hanspeter Gerber

Chief Scientific Officer, Sutro Biopharma

Exploring rationale for dual payload ADCs, combining synergetic efficacy of Topo1 payloads combined with diverse, alternative mechanisms to overcome patient resistance
Spotlighting comprehensive preclinical efficacy of dual payload ADCs across in vitro and in vivo models
Supporting promising efficacy results with preclinical pharmacology, PK/PD and safety profiles of dual cytotoxic conjugate

10:00 am Managing High-Potency & Environmental Priorities Through Sustainable Practices in Complex API Manufacturing

Rohtash Kumar

Senior Vice President & Chief Technology Officer, Veranova

Enacting innovative approaches to implement the Green Chemistry concept to ADC manufacturing
Developing clinical to commercial phase manufacturing processes to achieve improvement goals for environmental impact, safety, and economic value
Managing the supply chain for sustainable and reliable complex HPAPI and ADC manufacturing

10:30 am Morning Break & Networking

Scientific posters will be displayed all day. Use this dedicated time to meet poster authors and ask your burning questions

Discovery Preclinical & Translational Clinical Lessons Process & Analytical Development Manufacturing & Supply Chain

Discovery

Chair:

Hans-Georg Lerchen

Consultant, Independent Consultant

Exploring Rationale-Driven Approaches to Deliver ADC Payload & Target Differentiation

11:30 am Showcasing Tubulin Inhibitor Payload Innovation to Develop Novel ADCs & Subvert Patient Resistance to Established Mechanisms

Christian Rohlff

Chief Executive Officer, Oxford BioTherapeutics

Weighing up novel payload development through evolving existing payload classes versus pursuing novel mechanisms
Leveraging new and advanced tools to investigate novel tubulin payload development
Contextualising payload innovation through ADC programmes and understanding significance for nextgeneration ADC development

12:00 pm Blending Chemistry & Biology ADC Design: Exploring Rationale- Driven Development of ALX2004 to Maximise Opportunity for Clinical Differentiation

Marija Vrljic

Vice President, Antibody Technologies, ALX Oncology

Highlighting design and selection of novel Topo1 payload, highlighting rationale for pairing with anti-EFGR antibody
Presenting preclinical performance of ALX2004 including activity with improved bystander activity and stability versus deruxtecan ADCs
Sharing rationale and design to maximise therapeutic window and overcome toxicity challenges of the class

12:30 pm Session Presented By LICOR bio

Preclinical & Translational

Chair:

Rakesh Dixit

President & Chief Executive Officer, Bionavigen Oncology

Showcasing Lessons Learned From ADCs in IND-Enabling Translational Studies

11:30 am Innovating ADCs with Tubutecan Technology from Bench to Bedside: Highlighting Development of TUB-040, a NaPi2b-Targeting ADC

Saskia Schmitt

Director, Biology, Tubulis

Detailing comprehensive preclinical evaluation of TUB-040 and work leading to translation into the clinic
Explaining TUB-040 ADC design innovation across payload, conjugation and target
Highlighting the clinical development strategy and potential therapeutic impact of TUB-040

12:00 pm ZW191: Connecting ADC Preclinical Performance Insights to Clinical Potential

Stuart Barnscher

Senior Director, Preclinical Programs, ADC Therapeutic Development, Zymeworks

Introducing the in-depth preclinical profile of ZW191 targeting FRα
Understanding how the design elements of ZW191 manifested in preclinical performance
Looking ahead: Anticipating clinical impact and outcomes based on reported preclinical activity

12:30 pm Evaluating the Vast Array of Bioconjugate Data to Enhance ADC Development Strategy & Stay One Step Ahead of the Competition

Alistair Ellmer

Research Director, Hanson Wade Intelligence

Contextualising how the success of the ADC field has raised the bar for impactful ADC development strategy
Capturing the vast amount of ADC-related public data to understand market trends key areas of ADC innovation
Holding a lens to ADC public data to recognise the needs of the market and stay one step ahead of the competition

Clinical Lessons

Chair:

Venkatesh Pilla Reddy

Senior Director, Global PKPD & Pharmacometrics, Eli Lilly & Co.

Leveraging Biomarker & Imaging Strategies to Enhance ADC Performance in the Clinic

11:30 am Evaluating Intracranial Response with DXd ADCs & Other Biologics: Lessons Learned & Opportunities Ahead

David Leung

Head, Imaging, Daiichi Sankyo

Traditionally, large molecules including ADCs are thought to have no intracranial efficacy due to inability to cross the blood brain barrier
Presenting evidence of intracranial efficacy of multiple DXd ADCs and mAbs, challenging this dogma
Explaining this information can be utilised to address the unmet needs for patients with brain metastases

12:00 pm Leveraging Radio-Imaging to Characterise ADC In-Human Tumour Targeting & Accelerate Therapeutic Development

Gavin Bennett

Senior Director, BTC Portfolio Lead, Bicycle Therapeutics

Utilising radio-binders to monitor tracking and delivery of cytotoxic and radio-conjugates, tailored to different payload types
Delving into examples of radio-imaging to inform ADC target expression and PK/PD modelling
Understanding enhanced properties of non-antibody conjugates for different approaches to conjugates therapeutics

12:30 pm Roundtable Discussion: Evaluating the Need for Biomarker & Patient Selection Tools in an Increasingly Busy ADC Field

What is the current need and appetite for ADC biomarker development and patient selection strategies heading into 2025?
Discussing the different methodologies across machine learning and digital pathology to quantify IHC-derived ADC target expression
Addressing the challenges and opportunities of biomarker analysis to select patient populations to benefit from specific ADCs

Process & Analytical Development

Undergoing Sensitive ADC Impurity Characterisation & Control to Improve ADC Process Quality

11:30 am ADCs From a Bioanalytical Lab’s Perspective: LBA & LCMS/MS Two Different Solutions for Similar Questions

Daniel Schulz-Jander

Senior Director, Bioanalysis (Mass Spectrometry), QPS

Unveiling the diverse and complex bioanalytical dataset needs for successful development of ADCs – the bioanalytical lab as a key partner
Exploring approaches and types of data using LBA assays
Explaining approaches and types of data using mass spectrometric assays

12:00 pm Dissecting a Decrease in Cytotoxicity Observed For a Stressed ADC & Assessing Impact on Activity

Eef Dirksen

Head, Analytical Validation & Quality Control, Byondis

Laying out how ADCs combine the strengths of small and large molecules, thereby posing novel analytical challenges
Explaining how analytics are key in gauging the heterogeneity and complexity of ADCs
Undergoing a multidisciplinary approach required to evaluate the impact on safety and efficacy of any (new) ADC impurities

12:30 pm Session Presented By Intertek

12:45 pm Session Presented By Genovis

Manufacturing & Supply Chain

Understanding Best Practices For Scale-Up & Tech Transfer in Late-Stage ADC Manufacturing

11:30 am Enhancing ADC Development Through Integrated Chemistry & Technology

Lisa McDermott

Director, Senior Manager & Principal Scientist - Process & Analytical Development, Merck

Mary Ramisetty

Senior Scientist & Group Lead, Merck

Discussing an integrated platform approach that utilizes real-time PAT, engineering principles, and strategic methodologies
Outlining strategies for optimising conjugation chemistry and fostering collaboration among multidisciplinary teams to drive innovation
Exploring case studies to demonstrate how this approach enhances decision-making, reduce timelines, and improve cost efficiencies in the ADC pipeline

12:00 pm Roundtable Discussion: Debating the Challenges & Opportunities to Maximise Efficient Process Scale Up & Technology Transfer in Late-Stage ADC Manufacturing

Ryan O’Hara

Director, Biologics Technical Operations, MSD

Understanding strategies and considerations for commercial-stage ADC manufacturing
Debating the challenges of ensuring ADC process quality in late-stage manufacturing and tech transfer to external facilities
Understanding strategies for internal and external alignment to optimise ADC process and technology transfer

12:30 pm Mastering the Complexity of ADC Development: Expertise That Delivers Outlining mAb and bioconjugate capabilities and services

Matthieu Culie

Head, mAb & ADC Development & GMP Manufacturing, GTP Bioways

Exploring case studies for reduction and bconjugation optimisation
Breaking down case studies for mAb and ADC purification improvement

12:45 pm Session Presented By TAPI

1:00 pm Lunch & Learn Session Presentation Hosted By Merck

Invitation-only session. For all other attendees, lunch is provided in the exhibition area

Discovery Preclinical & Translational Clinical Lessons Process & Analytical Development Manufacturing & Supply Chain

Discovery

Utilising Novel Conjugation Chemistries to Enhance ADC Properties & Widen Therapeutic Index

2:00 pm Exploring a Comparative Study of Click Handle Stability in Common Ligation Conditions to Improve ADC Experimental Design

Caity Fawcett

Senior Scientist, GSK

Discussing click chemistry approaches for ADC synthesis
Assessing the compatibility of reagents used within click reactions with common conjugation conditions
Discussing lessons learned to guide selection of the most optimal combination of click chemistry and conjugation to streamline ADC experimental design

2:30 pm Summary Panel Discussion: What ADC Discovery Innovation is Showing the Most Promise

Hans-Georg Lerchen

Consultant, Independent Consultant

Re-join the discovery speakers for a closing panel discussion exploring the future directions of ADC discovery innovation. Engage with fellow attendees as they discuss novel payload trends, potential for payload combinations to overcome patient resistance, and the benefits of bispecific conjugates alongside classical ADC design.

Preclinical & Translational

Exploring Opportunities to De- Risk Development & Translation of Novel ADCs

2:00 pm Navigating Risk & Development Strategy to Bring Novel & First-in-Class ADCs to the Clinic

Elisabetta Leo

Senior Director, Early Development Asset Lead, Ipsen Pharma

Emphasising the importance of pursuing novel targets amongst a crowded clinical landscape to develop ADCs with meaningful patient impact
Contextualising learnings from progressing a novel target ADC to clinical trials
Incorporating learnings from historical profiles of adjacent target ADC:

What are the indications of promising performance?

2:30 pm Summary Panel Discussion: Evaluating Opportunities to Improve ADC Preclinical Characterisation & Translation

Rakesh Dixit

President & Chief Executive Officer, Bionavigen Oncology

Bring your questions to this closing panel session with your conference speakers. Hear them delve into CDX, PDX and in vitro model assessments, comprehensive preclinical data sets, and strategies to effectively translate novel ADC targets and conjugate formats to better predict ADC clinical activity.

Clinical Lessons

Planning ADC Clinical Development to Optimise ADC Positioning Within Patient Sequencing Regiments

2:00 pm Reaching the Higher Bar for ADC Success: Spotlighting IKS014 Clinical Performance & Understanding Driving Factors for Where ADCs Will Fit Into Treatment Paradigms

Jutta Deckert

Vice President, R&D, Iksuda Therapeutics

Highlighting clinical performance of IKS014 in Phase I development for the treatment of patients with advanced HER2+ solid tumours
Showcasing the promising preclinical profile of IKS04 targeting CA242 in gastrointestinal cancer
Addressing the concept of ADC sequencing in future treatment paradigms

2:30 pm Summary Panel Discussion: Exploring ADC Clinical Performance & Improving Clinical Design to Reach Meaningful Patient Benefit for ADCs

Venkatesh Pilla Reddy

Senior Director, Global PKPD & Pharmacometrics, Eli Lilly & Co.

Join the clinical and medical presenters to review the key learnings from the scientific programme days. Be sure to bring any questions across ADC clinical development strategy, dose escalation, biomarker-driven development, and ADC sequencing.

Process & Analytical Development

Optimising ADC Potency Assay Approaches to Improve Sensitivity of Efficacy Characterisation

2:00 pm Session Presented By Simtra

2:30 pm Summary Panel Discussion: Debating the Key Methodologies & Technologiess to Elevate ADC Process & Product Quality

Wrap up the two days of content with actionable insights to elevate your ADC process and analytics. Together with fellow attendees, discuss and debate the best ways to define ADC CQAs, undergo impurity characterisation and control, and energise bioassay development.

Manufacturing & Supply Chain

Tackling the Considerations & Challenges for ADC Manufacturing Facility Design

2:00 pm Session Presented By Schott Pharma

2:30 pm Integrating Occupational Health & Safety in Highly Potent Payload Facility Design Development

Justin Mason-Home

Director, HPAPI Project Services Limited

Bringing systematic and science-driven principles to ADC facility design planning
Understanding API occupational toxicological hazards and exposure risks from conjugate and payload manufacturing and containment
Using practical systematic science to support design of all ADC facilities

3:00 pm Afternoon Break & Networking

Showcasing Innovative ADC Design Philosophy to Elevate ADC Efficacy & Tolerability & Widen Therapeutic Index

4:00 pm Undergoing Kinder & Gentler ADC Development to Unlock Next-Generation, Earlier Line Patient Therapies

Mohit Trikha

President & Chief Operating Officer, Kivu Bioscience

Contextualising lessons learned from the current ADC clinical development landscape and advocating for an enhanced focus on addressing tolerability to improve ADC performance and success for patients
Pursuing less toxic ADC development to evolve dosing to be equivalent to naked antibody therapies and expand therapeutic index
Highlighting differentiation strategy for kinder and gentler ADC development, headlined with preclinical profile of KIVU-107 against solid tumours

4:30 pm Next-Generation Bioconjugate Therapeutics: Driving Innovation With Revolutionary Conjugation Technologies

Paul Song

Chief Scientific Officer, GeneQuantum Healthcare

Overviewing GeneQuantum’s holistic conjugation and manufacturing platforms: iLDC and iGDC
Introducing the world’s first rapid ADC screening system: iScreener
Empowering best-in-class and first-in-class XDC therapeutic development through GeneQuantum’s leading technology platform

5:00 pm CX-2051: Unlocking EpCAM as a Cancer Target via a Masked EPCAM-Directed Topo1 ADC

Sean McCarthy

Chief Executive Officer, CytomX Therapeutics

EpCAM is highly and uniformly expressed in CRC, but its normal tissue expression has precluded targeting EpCAM with systemic therapies
Introducing CX-2051 as a first-in-class masked EpCAM targeted Topo1 ADC with compelling preclinical profile and early Phase I data
CX-2051 is being rapidly advanced in the clinic in CRC with a path to expanding to other EpCAM expressing solid tumours

5:30 pm Chair’s Closing Remarks

Bob Lutz

Chief Scientific Officer, Iksuda Therapeutics

5:30 pm End of Scientific Programme Day Two

Day Two

Explore the Agenda

7:30 am Check In, Morning Coffee & Light Refreshments

8:25 am Chair’s Opening Remarks

Tackling the Necessity for Bioconjugate Design & Payload Innovation to Secure the Future of ADCs as Clinically Meaningful Oncology Therapies

8:30 am Fuelling the Next Generation of ADCs: Protein Alkylation Payloads & the Broader ADC Innovation Imperative

9:00 am Synaffix/Lonza End-to-End Offering to Best-in-Class Targeted-Therapies Based on GlycoConnect® & HydraSpace® Technologies

9:30 am Spotlighting Efficacy & Safety Profiles of Dual Payload ADCs Featuring Novel Linker Payloads to Overcome Resistance Mechanisms

10:00 am Managing High-Potency & Environmental Priorities Through Sustainable Practices in Complex API Manufacturing

10:30 am Morning Break & Networking

Discovery

Chair:

Exploring Rationale-Driven Approaches to Deliver ADC Payload & Target Differentiation

11:30 am Showcasing Tubulin Inhibitor Payload Innovation to Develop Novel ADCs & Subvert Patient Resistance to Established Mechanisms

12:00 pm Blending Chemistry & Biology ADC Design: Exploring Rationale- Driven Development of ALX2004 to Maximise Opportunity for Clinical Differentiation

12:30 pm Session Presented By LICOR bio

1:00 pm Lunch & Learn Session Presentation Hosted By Merck

Utilising Novel Conjugation Chemistries to Enhance ADC Properties & Widen Therapeutic Index

2:00 pm Exploring a Comparative Study of Click Handle Stability in Common Ligation Conditions to Improve ADC Experimental Design

2:30 pm Summary Panel Discussion: What ADC Discovery Innovation is Showing the Most Promise

3:00 pm Afternoon Break & Networking

Showcasing Innovative ADC Design Philosophy to Elevate ADC Efficacy & Tolerability & Widen Therapeutic Index

4:00 pm Undergoing Kinder & Gentler ADC Development to Unlock Next-Generation, Earlier Line Patient Therapies

4:30 pm Next-Generation Bioconjugate Therapeutics: Driving Innovation With Revolutionary Conjugation Technologies

5:00 pm CX-2051: Unlocking EpCAM as a Cancer Target via a Masked EPCAM-Directed Topo1 ADC

5:30 pm Chair’s Closing Remarks

5:30 pm End of Scientific Programme Day Two

Venue

Map

Contact

Join Our Team

About Us

Explore Our Products

Stay Connected

Search

Organised By